These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16200940)

  • 1. [News in the management of calcium and phosphorus metabolism disorders for patient treated by hemodialysis].
    Van Overmeire L; Delanaye P; Krzesinski JM
    Rev Med Suisse; 2005 Aug; 1(30):1960-5. PubMed ID: 16200940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent advances in the prevention of cardiovascular morbidity and mortality in end-stage renal disease: role of anemia, hyperparathyroidism and calcifications].
    Del Vecchio L; Pozzoni P; Limardo M; Caruso S; Fortunato M; Pontoriero G; Locatelli F
    G Ital Nefrol; 2007; 24 Suppl 38():25-32. PubMed ID: 17922444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disordered calcium and phosphorus metabolism during maintenance hemodialysis. Correlation of clinical, roentgenographic and biochemical changes.
    Parfitt AM; Massry SG; Winfield AC; DePalma JR; Gordon A
    Am J Med; 1971 Sep; 51(3):319-30. PubMed ID: 5115990
    [No Abstract]   [Full Text] [Related]  

  • 5. Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration.
    Gotch F; Levin NW; Kotanko P
    Blood Purif; 2010; 29(2):163-76. PubMed ID: 20093823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to minimize bone disease in renal failure.
    Martin KJ; González EA
    Am J Kidney Dis; 2001 Dec; 38(6):1430-6. PubMed ID: 11728986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia].
    Morio K; Koide K
    Nihon Rinsho; 1995 Apr; 53(4):958-64. PubMed ID: 7752492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized Management of Bone and Mineral Disorders and Precision Medicine in End-Stage Kidney Disease.
    Jovanovich A; Kendrick J
    Semin Nephrol; 2018 Jul; 38(4):397-409. PubMed ID: 30082059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
    McCarley PB; Arjomand M
    Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary hyperparathyroidism in chronic kidney disease: clinical consequences and challenges.
    Michael M; Garcia D
    Nephrol Nurs J; 2004; 31(2):185-94; quiz 195-6. PubMed ID: 15114799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy for ROD and measurement of the bone mass].
    Yamamoto I; Kawamura Y; Hirano K; Hayakawa H; Shigematu T
    Clin Calcium; 2004 Dec; 14(12):83-8. PubMed ID: 15577179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of calcium and phosphorus on patients maintained on dialysis.
    Goldsmith RS; Arnaud CD; Johnson WJ
    Kidney Int Suppl; 1975 Jan; (2):118-22. PubMed ID: 1099298
    [No Abstract]   [Full Text] [Related]  

  • 14. Azotaemic osteodystrophy-present position.
    Malhotra KK
    J Assoc Physicians India; 1978 Sep; 26(9):827-35. PubMed ID: 370080
    [No Abstract]   [Full Text] [Related]  

  • 15. [Calcium and phosphate metabolism in dialysis patients].
    Nakazawa R
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():108-13. PubMed ID: 15250278
    [No Abstract]   [Full Text] [Related]  

  • 16. [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].
    Brancaccio D; Cozzolino M; Galassi A; Bellasi A; Carpani P; Gallieni M
    G Ital Nefrol; 2003; 20 Suppl 22():S12-6. PubMed ID: 12851915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].
    Goto S; Fukagawa M
    Clin Calcium; 2007 Dec; 17(12):1830-4. PubMed ID: 18057657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of bone remodeling: impact of novel therapies.
    Hercz G
    Semin Dial; 2001; 14(1):55-60. PubMed ID: 11208041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adequate Ca level for dialysis patient (study on medical therapy for secondary hyperparathyroidism in dialysis patient)].
    Sawada K; Sawada S; Nakagawa M; Ioka J; Tatsumi T; Yoneda Y; Maki K
    Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):813-9. PubMed ID: 1479721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.